Dr. Inna Lazar presents at AAOPT 2025: Demodex Blepharitis
FOR IMMEDIATE RELEASE
October 12, 2025
New Case Report Presented at American Academy of Optometry 2025 Highlights Resolution of
Refractory Demodex Blepharitis with Innovative Eyelid Irrigation Approach
[Wildwood, PA] — At the 2025 American Academy of Optometry Annual Meeting, a novel case report
was presented demonstrating the successful treatment of persistent Demodex-associated ocular
surface disease using Rinsada, a procedure that could represent a significant advancement in managing
persistent ocular surface inflammation.
The presentation, titled “Resolution of Refractory, Symptomatic Demodex Blepharitis-Associated
Conjunctival Staining Following Treatment with an Irrigating Eyelid Retractor: A Case Report,”
documents a unique case in which conventional therapy—lotilaner ophthalmic solution 0.25%
(Xdemvy™)—was insufficient to fully resolve ocular surface disease linked to Demodex infestation.
The patient, who initially presented with classic symptoms of bilateral eyelid irritation, crusting,
tearing, grittiness, and foreign body sensation, was diagnosed with Demodex blepharitis based on slitlamp
evidence of collarettes. Despite a six-week course of lotilaner, the patient continued to experience
discomfort and showed persistent conjunctival staining on both the bulbar and palpebral conjunctiva.
In response to these refractory symptoms and signs of surface inflammation, clinicians performed a
complete ocular lavage using an irrigating eyelid retractor, a mechanical device designed to flush debris
and inflammatory biofilm from the lid margin and conjunctival fornix. At follow-up several weeks postprocedure,
the patient exhibited complete resolution of symptoms and conjunctival staining.
"This case underscores the overlooked role of Demodex as a vector for bacteria that may colonize the
conjunctival fornices," said Dr. Inna Lazar, OD, Owner, Greenwich Eye Care. "It also highlights the
therapeutic value of mechanical intervention in patients who do not fully respond to pharmacologic
treatment alone."
This report is among the first to detail the use of an irrigating eyelid retractor as a successful adjunct
therapy in Demodex blepharitis with conjunctival involvement, expanding the understanding of the
mite’s impact on the ocular surface ecosystem.
The findings may inform future treatment protocols for optometrists and ophthalmologists managing
chronic blepharitis, especially in patients with persistent symptoms despite standard Demodex-targeted
therapy.
About Rinsada
Rinsada is a sterile, single-use, FDA-cleared Class I irrigating eyelid retractor indicated for the removal of
ocular surface irritants. Headquartered in Wildwood, Pennsylvania, Rinsada is currently in use at more
than 250 eyecare practices across the United States and is also available through the U.S. Federal Fee
Schedule Contract.
Media Contact
Joe Boyd
Rinsada Strategic Advisor
joe.boyd@rinsada.com
214.912.7664
Full information can be found here.
